Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Maat B, Van Limbergen E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Radiother Oncol. 2000 Jun;55(3):219-32. doi: 10.1016/s0167-8140(00)00210-3. Radiother Oncol. 2000. PMID: 10869738 Clinical Trial.
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.
Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Antonini N, et al. Among authors: poortmans p. Radiother Oncol. 2007 Mar;82(3):265-71. doi: 10.1016/j.radonc.2006.09.014. Epub 2006 Nov 28. Radiother Oncol. 2007. PMID: 17126434 Clinical Trial.
Reducing interobserver variation of boost-CTV delineation in breast conserving radiation therapy using a pre-operative CT and delineation guidelines.
Boersma LJ, Janssen T, Elkhuizen PH, Poortmans P, van der Sangen M, Scholten AN, Hanbeukers B, Duppen JC, Hurkmans C, van Vliet C. Boersma LJ, et al. Among authors: poortmans p. Radiother Oncol. 2012 May;103(2):178-82. doi: 10.1016/j.radonc.2011.12.021. Epub 2012 Jan 20. Radiother Oncol. 2012. PMID: 22265730
Radiotherapy for elderly patients with low-risk breast cancer.
Kaidar-Person O, Poortmans P, Kuten A, Morgan DA. Kaidar-Person O, et al. Among authors: poortmans p. Lancet Oncol. 2015 May;16(5):e196-7. doi: 10.1016/S1470-2045(15)70063-X. Lancet Oncol. 2015. PMID: 25943058 No abstract available.
Over-irradiation.
Poortmans PMP, Arenas M, Livi L. Poortmans PMP, et al. Breast. 2017 Feb;31:295-302. doi: 10.1016/j.breast.2016.07.022. Epub 2016 Aug 10. Breast. 2017. PMID: 27522160 Review.
The 2016 Assisi Think Tank Meeting on breast cancer: white paper.
Aristei C, Kaidar-Person O, Arenas M, Coles C, Offersen BV, Bourgier C, Frezza G, Leonardi MC, Valentini V, Poortmans PM. Aristei C, et al. Among authors: poortmans pm. Breast Cancer Res Treat. 2016 Nov;160(2):211-221. doi: 10.1007/s10549-016-3998-2. Epub 2016 Sep 29. Breast Cancer Res Treat. 2016. PMID: 27686462
431 results